List of works - Thomas Mühlenberg

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth

scientific article published on 4 February 2013

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

scientific article published in 2024

Covalent-Allosteric Kinase Inhibitors.

scientific article published on 25 June 2015

DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.

scientific article published on 10 April 2013

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor

scientific article published on 22 February 2017

Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.

scientific article

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib

scientific article published on 04 May 2016

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.

scientific article

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR

scientific article

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy

scientific article published on 15 July 2019

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

scientific article

Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells

scientific article

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour

scientific article published on 17 February 2012

Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain

scientific article published on 24 September 2020

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors

scientific article published on 14 May 2013

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors

scientific article

List of works by Thomas Mühlenberg

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

Covalent-Allosteric Kinase Inhibitors.

DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor

Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour

Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors